Matches in SemOpenAlex for { <https://semopenalex.org/work/W2891969324> ?p ?o ?g. }
Showing items 1 to 66 of
66
with 100 items per page.
- W2891969324 abstract "e23110 Background: MET gene, encoding the tyrosine kinase receptor for HGF, has been shown to have an oncogenic role in several tumors. We report here the frequency, distribution and clinical characteristics of the patients (pts) found to have MET alterations in a molecular screening trial. Methods: InMOSCATO clinical trial, pts with locally advanced or metastatic solid cancers had an on-purpose tumor biopsy to perform a comprehensive molecular characterization. Results: Among the 844 adult pts who had a successful molecular portrait, 29 (3.4%) had MET aberrations distributed as follows: 18 had abnormalities at the genomic analysis level while 11 had exclusively expression of phosporylated-MET by immunohistochemistry (IHC) and/or a positive fluorescence in situ hybridization (FISH). Only one of the 74 pediatric pts included had a missense mutation. According to the primary tumor, MET alterations were found in 13/170 successfully biopsied pts with lung cancer, 8/197 with digestive tumors, 3/158 with genito-urinary tumors, 2/83 with gynecologic tumors, 2/111 with head and neck cancers, 1/135 with breast cancer and 1 pt with pediatric glioblastoma. Pathogenic variants (PV) were detected in 3 pts by targeted Next Generation Sequencing (NGS), 2 of these PV were exon 14 donor splice site mutations detected also by whole-exome sequencing (WES) in 2 lung tumors. Missense mutations were identified in 3 pts by RNA-sequencing and in one patient by WES. 8 pts had MET amplification identified by comparative genomic hybridization array (CGH) in 5 cases, by FISH in one case and by both FISH and CGH in 2 cases. One patient displayed both amplification and a missense mutation. Ten pts received an anti-MET targeted therapy. One had PV on NGS and missense mutation on WES, 3 had amplification on CGH or FISH and 6 positive IHC. One patient displaying MET exon 14 donor splice site mutation was treated with crizotinib achieving a rapid and sustained partial response. The other 9 pts were treated with SAR125844, a selective MET tyrosine kinase inhibitor, in TED11449 trial (NCT01391533). Conclusions: In this analysis, we saw that MET aberrations are rare in various types of advanced cancers. In selected patients, targeting MET is of clinical interest. Clinical trial information: NCT01566019." @default.
- W2891969324 created "2018-09-27" @default.
- W2891969324 creator A5003964504 @default.
- W2891969324 creator A5012110476 @default.
- W2891969324 creator A5021624793 @default.
- W2891969324 creator A5024750258 @default.
- W2891969324 creator A5028436035 @default.
- W2891969324 creator A5036048236 @default.
- W2891969324 creator A5042575799 @default.
- W2891969324 creator A5047923667 @default.
- W2891969324 creator A5079058944 @default.
- W2891969324 creator A5086593040 @default.
- W2891969324 creator A5090082356 @default.
- W2891969324 date "2017-05-20" @default.
- W2891969324 modified "2023-10-17" @default.
- W2891969324 title "MET aberrations across multiple tumor types: Results of a molecular screening program (MOSCATO 01)." @default.
- W2891969324 doi "https://doi.org/10.1200/jco.2017.35.15_suppl.e23110" @default.
- W2891969324 hasPublicationYear "2017" @default.
- W2891969324 type Work @default.
- W2891969324 sameAs 2891969324 @default.
- W2891969324 citedByCount "0" @default.
- W2891969324 crossrefType "journal-article" @default.
- W2891969324 hasAuthorship W2891969324A5003964504 @default.
- W2891969324 hasAuthorship W2891969324A5012110476 @default.
- W2891969324 hasAuthorship W2891969324A5021624793 @default.
- W2891969324 hasAuthorship W2891969324A5024750258 @default.
- W2891969324 hasAuthorship W2891969324A5028436035 @default.
- W2891969324 hasAuthorship W2891969324A5036048236 @default.
- W2891969324 hasAuthorship W2891969324A5042575799 @default.
- W2891969324 hasAuthorship W2891969324A5047923667 @default.
- W2891969324 hasAuthorship W2891969324A5079058944 @default.
- W2891969324 hasAuthorship W2891969324A5086593040 @default.
- W2891969324 hasAuthorship W2891969324A5090082356 @default.
- W2891969324 hasConcept C126322002 @default.
- W2891969324 hasConcept C143998085 @default.
- W2891969324 hasConcept C71924100 @default.
- W2891969324 hasConceptScore W2891969324C126322002 @default.
- W2891969324 hasConceptScore W2891969324C143998085 @default.
- W2891969324 hasConceptScore W2891969324C71924100 @default.
- W2891969324 hasLocation W28919693241 @default.
- W2891969324 hasOpenAccess W2891969324 @default.
- W2891969324 hasPrimaryLocation W28919693241 @default.
- W2891969324 hasRelatedWork W1586151303 @default.
- W2891969324 hasRelatedWork W1960850967 @default.
- W2891969324 hasRelatedWork W2001904524 @default.
- W2891969324 hasRelatedWork W2013366650 @default.
- W2891969324 hasRelatedWork W2058658410 @default.
- W2891969324 hasRelatedWork W2113443504 @default.
- W2891969324 hasRelatedWork W2140266186 @default.
- W2891969324 hasRelatedWork W2141813430 @default.
- W2891969324 hasRelatedWork W2157423592 @default.
- W2891969324 hasRelatedWork W2159936790 @default.
- W2891969324 hasRelatedWork W2160212814 @default.
- W2891969324 hasRelatedWork W2319704925 @default.
- W2891969324 hasRelatedWork W2523818766 @default.
- W2891969324 hasRelatedWork W2573565484 @default.
- W2891969324 hasRelatedWork W2585904702 @default.
- W2891969324 hasRelatedWork W2602533179 @default.
- W2891969324 hasRelatedWork W2954480559 @default.
- W2891969324 hasRelatedWork W2961566889 @default.
- W2891969324 hasRelatedWork W2988827769 @default.
- W2891969324 hasRelatedWork W3153745588 @default.
- W2891969324 isParatext "false" @default.
- W2891969324 isRetracted "false" @default.
- W2891969324 magId "2891969324" @default.
- W2891969324 workType "article" @default.